1. Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology.
- Author
-
Mattuizzi A, Sauvestre F, Fargeix T, White E, Leibler C, Cargou M, Dugot-Senant N, Douchet I, Duluc D, Bordes C, Truchetet MÉ, Richez C, Forcade É, Duffau P, Viallard JF, Sentilhes L, Blanco P, and Lazaro E
- Subjects
- Humans, Female, Pregnancy, Adult, Interleukin-1beta metabolism, Interleukin-1beta genetics, Placenta metabolism, Placenta pathology, CARD Signaling Adaptor Proteins genetics, CARD Signaling Adaptor Proteins metabolism, Pregnancy Outcome, Recurrence, Infant, Newborn, Chorionic Villi metabolism, Chorionic Villi pathology, Chronic Disease, Inflammasomes metabolism, NLR Family, Pyrin Domain-Containing 3 Protein metabolism, NLR Family, Pyrin Domain-Containing 3 Protein genetics, Placenta Diseases pathology, Placenta Diseases drug therapy, Interleukin 1 Receptor Antagonist Protein therapeutic use
- Abstract
Chronic histiocytic intervillositis of unknown origin (CHI) is a rare placental disorder associated with adverse pregnancy outcomes, frequent recurrence, and a lack of effective preventive strategies. Recent insights indicate a potential link between CHI-associated inflammatory lesions and the inflammasome pathway, suggesting innovative therapeutic avenues. Here we show a potential role of the inflammasome pathway in CHI through comprehensive transcriptomic analysis of grade 2 or 3 histopathologic CHI samples, paired with placental controls. Additionally, we present case studies of three individuals with recurrent CHI, who have undergone treatment with anakinra and colchicine throughout pregnancy, resulting in improved perinatal outcomes. Notably, all cases are characterized by the birth of healthy, full-term infants, with reduced or absent intervillositis recurrence. Placental assessment unveils heightened activation of the NLRP3-PYCARD inflammasome pathway and IL-1β processing in CHI samples, with downregulation observed in treated pregnancy samples, devoid of intervillositis. Collectively, these findings suggest a potential therapeutic role for targeting the inflammasome pathway in preventing recurrent CHI in pregnant individuals., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF